Are High Costs of Newer Diabetes Drugs Deterring Eligible Patients?

(MedPage Today) -- Fewer than 10% of eligible U.S. patients with type 2 diabetes used a GLP-1 receptor agonist or SGLT2 inhibitor, according to nationally representative data. While it was estimated that 22.4 million U.S. adults with diagnosed...
Source: MedPage Today Nephrology - Category: Urology & Nephrology Source Type: news